Cogent Biosciences Inc COGT shared data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis…
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, discussed the updated findings from the phase 3 ALPINE trial of zanubrutinib vs ibrutinib in relapsed/refractory CLL (r/r CLL) at 39 months of follow-up.
ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma Expect to commence Phase 1/2 clinical trial in China.